Objective: To carry out a critical review of published studies concerning the treatment of provoked vestibulodynia.
D
escribed over a century ago, 1 provoked vestibulodynia is recognized as the most frequent cause of dyspareunia in premenopausal women. 2, 3 Recent epidemiologic data suggest that vestibulodynia affects 12% of the general population, 4 and another study reported a 15% prevalence rate in gynecologic clinics. 3 Further, urogenital pain has serious repercussions on many aspects of daily functioning, namely sexual function, dyadic adjustment, psychologic well-being, and quality of life. [5] [6] [7] According to Friedrich, 2 provoked vestibulodynia is characterized by (1) severe pain upon vestibular touch or attempted vaginal entry, (2) acute pain during cotton swab palpation of the vestibular area, and (3) vestibular erythema. The reliability of the third criterion has however been disconfirmed by 2 recent studies. 8, 9 Despite the significant prevalence and negative impact of vestibulodynia, progress concerning the study of its treatment has been slow. Although a wide variety of surgical, medical, behavioral, cognitive-behavioral, and alternative treatments have been proposed and some treatment guidelines have been issued, [10] [11] [12] [13] no consensus exists concerning the standard algorithm to follow. This absence of consensus can be explained in part by a lack of knowledge concerning the etiology of vestibulodynia, hence the trial and error treatment process. Nevertheless, the proposed treatment guidelines are devoid of a scientific basis mostly because until recently, there was a paucity of rigorous studies focusing on the evaluation of available interventions. Indeed, in a critical review published in 1997, Bergeron et al 14 concluded that treatment efforts were largely based on uncontrolled clinical observations given the absence of prospective randomized clinical trials.
There has been a substantial increase in the number of studies relating to provoked vestibulodynia, particularly in the treatment domain since 1997. However, there has not been a comprehensive review of the literature synthesizing the therapeutic knowledge accumulated over the past 10 years. The goal of the present article is to critically review vestibulodynia treatment studies published since 1997, 14 with an emphasis on pain and sexual function outcomes. treatment of provoked vestibulodynia. Given that the review of Bergeron et al 14 covered studies published until 1995, the present search encompassed articles published in English between January 1996 and December 2006. The following keywords were used in MEDLINE and PsycINFO: ()vulvar vestibulitis* or )vestibulodynia* or )vulvar dysesthesia* or )dyspareunia* or )sexual pain disorders* or )genital pain syndromes*) and ()treatment* or )management*). As for the Cochrane database, the keywords )vulvar vestibulitis* and )vestibulodynia* were used by selecting the tab )search all text*. The reference lists of the identified treatment studies and reviews were also examined to target all other relevant literature.
Overall, the search strategy identified 962 potential articles concerning genital pain, of which 789 articles in MEDLINE, 163 in PsycInfo, and 10 in Cochrane. However, the PsycINFO and Cochrane searches identified the same treatment studies as the MEDLINE search. After having viewed the title, abstract, reference list, and, if necessary, the full article, all studies specifically concerning the treatment of provoked vestibulodynia were included in the review. Thus, studies were not excluded on the basis of the research design, sample size, or any other factor concerning methodological quality. Consequently, a total of 38 treatment studies were included. It is to be noted that some studies may have compared 2 or more therapeutic modalities and therefore appear in more than one section of this article.
RESULTS
Treatments for provoked vestibulodynia can be divided into 4 distinct categories: surgical, medical, behavioral/cognitive-behavioral, and alternative treatments. The 14 surgical treatment studies are described in Table 1 , whereas the 14 medical treatment studies are presented in Table 2 . Finally, the 6 behavioral/cognitivebehavioral treatment studies and the 5 alternative treatment studies appear in Table 3 . The studies are presented in the tables in the order of appearance in the text.
Surgical Treatment
In their 1997 review, Bergeron et al 14 concluded that the main surgical treatment, vestibulectomy, was the intervention that was the most frequently studied and that achieved the best success rates. Though having received less empirical attention since 1997, surgery has been the object of studies of higher methodological quality in the past decade (Table 1) .
Vestibulectomy, often referred to as modified perineoplasty, typically consists of the excision of the posterior hymen and of the painful mucosa of the posterior and anterior vestibule to a depth of about 2 to 5 mm. If necessary, the vaginal mucosa is mobilized, brought downward to cover the excised region, and held in place with sutures. 2, 24, 52 Vestibulectomy is generally recommended after the failure of less invasive medical treatments.
14 Two other types of surgical treatments also exist: Woodruff and Parmley's 53 original perineoplasty (less used today and consisting of elongating the excision down to the perineum) and modified vestibulectomy (limits the excision to the posterior fourchette of the vestibular area). 20 Among the 14 studies focusing on the surgical treatment of provoked vestibulodynia, 6 are retrospective. First, Chaim et al 15 showed that 94% of women reported an overall improvement of their dyspareunia after modified perineoplasty. Gaunt et al 16 found a similar success rate, with 90% of participants having significant relief of their pain. Bergeron et al's 5 study showed that 63% of women experienced a significant pain reduction and that sexual functioning significantly improved. However, 1 woman asserted that her pain worsened after vestibulectomy, and 2 women for whom the surgery had initially been effective indicated a return of their pain. Traas et al's 17 retrospective study included a larger number of participants, 62% of whom reported having no more pain and 73% who claimed to be satisfied with their sex life after vestibulectomy. However, 39% of the women mentioned having had long-term complications since the surgery, the most frequent complication being decreased lubrification. In a similar study conducted by Goldstein et al, 18 77% of participants reported having either no more pain or a negligible discomfort and 87% affirmed having a better sex life. Last, McCormack and Spence 19 obtained comparable results using the original perineoplasty, with 80% of participants reporting an improvement of their dyspareunia.
The 6 prospective studies showed similar results to those generated via retrospective designs. First, in Goetsch' study, 20 83% of women had complete relief of their pain after regular or modified vestibulectomy. However, 42% declared suffering from vaginismus after the surgery, which was resolved with the assistance of their partner or with desensitization therapy. Using a larger sample, Bornstein et al 21 found that 76% of participants reported a complete relief of their pain. Likewise, 83% of Schneider et al's 22 participants reported a moderate to excellent improvement of dyspareunia. However, minor postsurgery complications were noted by 15% of women (eg, severe pruritus, heavy bleeding, local infection, Bartholin duct stenosis) and a second surgery was required for 17% of participants. In the only study including a no-treatment control group, Granot et al's 23 participants chose either to have a vestibulectomy, one of 3 nonsurgical treatments (ie, biofeedback, cognitivebehavioral therapy, or use of hypoallergic agents), or no treatment. Results showed that 79% of participants who underwent vestibulectomy experienced a significant reduction of vulvar pain, whereas this success rate was 48% for those who received nonsurgical treatments and 12% for the no-treatment group. Despite these interesting results, participants in the nonsurgical treatment group did not all receive the same treatment, which makes it impossible to distinguish the success attributable to each intervention. Finally, 2 modified vestibulectomy studies showed similar results to other prospectively investigated HPV indicates human papillomavirus; N, sample size; X, mean. *1 = no control/comparison group; 2 = no random assignment; 3 = nonblind treatment evaluation; 4 = no definition of therapeutic success; 5 = little or no information on sample characteristics; 6 = some participants received another form of treatment between surgery and follow-up. N indicates sample size; sEMG, surface electromyography; VAS, Visual Analog Scale. *1 = no control/comparison group; 2 = no placebo group; 3 = no random assignment; 4 = nonblind treatment evaluation; 5 = no definition of therapeutic success; 6 = little or no information on sample characteristics; 7 = no treatment adherence evaluation. N indicates sample size; X, mean; sEMG, surface electromyography. *1 = no control/comparison group; 2 = no random assignment; 3 = nonblind treatment evaluation; 4 = no definition of therapeutic success; 5 = little or no information on sample characteristics; 6 = no treatment adherence evaluation; 7 = some participants received another form of treatment between the intervention and follow-up. 24, 25 Two randomized clinical trials examined surgical treatment. Bornstein and Abramovici 26 compared the efficacy of total perineoplasty (ie, with excision of the anterior vestibule) to partial perineoplasty (ie, without excision of the anterior vestibule) plus interferon injections in the anterior vestibule. Findings revealed no significant difference between the 2 groups, with 67% of participants in the total perineoplasty group having a complete response to treatment compared with 70% in the partial perineoplasty with interferon group. Moreover, only minor side effects of interferon injections were observed, whereas excessive postoperative bleeding occurred in 1 woman who underwent total perineoplasty. Nevertheless, given the absence of a partial perineoplasty group without interferon, it is impossible to know whether or not interferon injections significantly improve the surgery's efficacy.
Last, by means of a randomized clinical trial, Bergeron et al 27 compared the efficacy of vestibulectomy to that of 2 behavioral treatments-biofeedback and cognitive-behavioral group therapy (CBGT). Pain reduction was twice as high for participants who had the vestibulectomy than those who participated in one of the behavioral treatments, with 68% of vestibulectomy participants reporting complete or significant pain relief. Despite these encouraging results, 9% of the vestibulectomy participants stated that their pain worsened at follow-up, whereas no such deterioration was signaled by the participants of the 2 other groups.
As shown in Table 1 , the surgical treatment studies have several major methodological limitations. Indeed, only 2 studies are randomized and the great majority of studies have no control or comparison group. Moreover, most of the studies do not include a double-blind evaluation process nor provide an a priori definition of therapeutic success. As well, about half of the publications concerning surgery contain an inadequate description of their sample, which greatly complicates the comparison of studies. Half of the studies fail to provide a baseline pain measure, conducting only a posttreatment evaluation. Furthermore, the follow-up periods vary not only from one study to the next, but also within studies. Surgical techniques also differ between studies. In addition, the majority of studies evaluate pain subjectively, using a rudimentary qualitative scale despite the fact that better standardized evaluation methods exist (eg, cotton swab test for pain evaluation at each vestibular site, the McGill Pain Questionnaire). 54 Finally, almost half of the authors mention that the participants have received other forms of treatment between surgery and follow-up, which makes it impossible to distinguish the efficacy of the surgery from that of other treatments received. Despite those methodological limitations, when we compare its positive impact on pain reduction to the relatively low number of reported risks and complications, surgery is at present a sound treatment optionalbeit not a first line intervention. Future studies focusing on who benefits most from this procedure would help to further reduce the risk of failure.
Medical Treatments
Bergeron et al 14 stated in their 1997 review that medical treatments were largely underinvestigated, especially considering their prevalent use. In fact, being less invasive than vestibulectomy, medical interventions are frequently prescribed as the first attempt to relieve vulvar pain. Nevertheless, their degree of efficacy was still scarcely documented until recently. In the last 10 years, 14 studies focusing on medical treatments have been published. They can be divided into 3 categories: topical applications, systemic medications, and injections (Table 2) .
First, 5 studies examined whether the localized application of different medicated creams helps to alleviate the pain of provoked vestibulodynia. Steinberg et al 28 retrospectively evaluated the effects of capsaicin 0.025% applied daily for 12 weeks. Although results showed a significant improvement of dyspareunia, the authors did not indicate the specific number of participants for whom the treatment proved successful. Moreover, given the preventive application of lidocaine, it is impossible to isolate the effect of capsaicin. Murina et al 29 also studied the application of capsaicin cream preceded by a preventive application of lidocaine, but did so with a prospective design, a higher dosage, and a longer treatment duration. Results showed that 59% of participants reported an improvement of their pain symptoms. However, the symptoms reappeared about 15 days after discontinuation of capsaicin. As well, despite the preventive application of lidocaine, all participants indicated an intense burning sensation for 40 to 60 minutes after capsaicin application. Lidocaine 5% was also examined as a treatment in and of itself in a prospective study by Zolnoun et al. 30 After a localized, nightly application for about 7 weeks, 57% of the women indicated a reduction of their dyspareunia by at least 50%.
Morrison et al 31 prospectively examined the efficacy of ketoconazole 2% applied 3 times daily on the vulvar region of women with provoked vestibulodynia. Results revealed a complete recovery or improvement of pain for 44% of participants. Last, Nyirjesy et al 32 conducted the only placebo-controlled randomized, double-blind clinical trial, concerning the efficacy of a topical application, namely cromolyn 4%, applied locally for a period of 3 months. Results showed that the difference in symptom reduction between the participants in the treatment group (54%) and those in the placebo group (38%) was not significant.
Four treatment studies focusing on the use of systemic medications were identified. Pagano 33 prospectively examined the efficacy of a pain management protocol including xylocaine and either: (1) ketoconazole or fluconazole, (2) amitriptyline, or (3) carbamazepine. Results revealed a success rate of 67% for the oral antifungal treatment, 60% for amitriptyline, and 13% for carbamazepine. Bornstein et al 34 placebo group concerning oral agents. After following a regimen of 1 pill per week during 6 months, there was no significant difference between the treatment group and the placebo group, with success rates reaching 15% and 30%, respectively. Two nonexperimental studies concerning systemic medications focused on amitriptyline. Munday's 35 retrospective study showed that 45% of participants reported a complete response to the treatment. Nonetheless, given that some participants also benefited from psychotherapy, it is impossible to attribute improvement exclusively to amitriptyline. In contrast, the prospective study by Schmidt et al 36 showed that participants did not report a significant improvement in their vulvar symptoms or quality of life after their amitriptyline treatment. However, the small sample size or the low baseline pain level could possibly explain these nonsignificant results. Moreover, although the authors calibrated the dosage for each participant, the side effect profile of amitriptyline remains a downside of this intervention. Though administered at doses lower than for the treatment of depression, this type of medication may have negative side effects on sexuality, such as diminished sexual arousal, which may contribute to an increase in pain. 55 Five studies investigated whether specific types of injections might help decrease vulvar pain. In a case study, Segal et al 37 examined the effects of subcutaneous injections of betamethasone (corticosteroid) plus lidocaine administered at 1-week intervals in the vestibule. At follow-up, the participant indicated a complete relief of her pain and a good quality of sex life. The efficacy of methylprednisolone injections (corticosteroid) plus lidocaine were studied prospectively by Murina et al. 38 Results revealed that 32% of participants had a complete remission of their pain symptoms and 36% had a marked improvement.
The 3 other studies involving injections focused on botulinum toxin A, which essentially aims to reduce hypertonicity of pelvic floor muscles. In a case study by Romito et al, 39 the 2 participants reported complete pain relief within 2 to 7 days after the injections, for a duration of 5 to 6 months. Brown et al 40 conducted a similar case study where one participant indicated a modest reduction of her pain whereas the other participant reported very little reduction. Last, Dykstra and Presthus 41 conducted a pilot study with 12 patients who reported a significant reduction of their pain for a duration of 8 to 14 weeks after the injection, with a higher dosage leading to a longer lasting effect. Nevertheless, only 25% of patients reported a significant improvement of their quality of life upon follow-up. The different results obtained in those 3 studies are most probably explained by the fact that the optimum dose and injection technique of botulinum toxin still remain to be determined.
In general, the medical treatment research has the same methodological limitations as that pertaining to surgery (Table 2) . Among others, the great majority of studies was neither randomized nor double-blind, and did not provide an a priori definition of therapeutic success. However, the medical treatment studies more often included an adequate description of their sample and pretreatment and posttreatment pain evaluations, in addition to using more objective measures of pain. Unfortunately, treatment compliance was rarely assessed in the studies reviewed, which complicates the interpretation of results. As well, many studies combine their principal treatment with the application of an analgesic cream, which constitutes a treatment in and of itself (eg, lidocaine). Furthermore, the studies involving local injections have a very small number of patients, which limits the conclusions that can be drawn. Last, despite the large placebo effect detected in the study by Nyirjesy et al 32 and Bornstein et al, 34 only 2 studies included a placebo group. Notwithstanding those methodological limitations, it seems that when we take account (1) the impact of the treatment on pain reduction, (2) the profile of side effects, and (3) the quality of the different studies, lidocaine 5% applied daily and combined injections of both corticosteroid and lidocaine stand out as 2 promising medical treatments. However, more controlled studies are necessary to further document up to what point medical treatments significantly relieve the pain of women with provoked vestibulodynia.
Behavioral and Cognitive-behavioral Treatments
In 1997, only one study on biofeedback and one on behavioral sex therapy had been published. Since then, biofeedback has become more popularized, with 4 studies supporting its usefulness, whereas cognitive-behavioral therapy remains marginalized to some extent, although 2 more studies attesting to its value have been published in the last decade (Table 3) .
Biofeedback is largely used to treat various types of chronic or recurrent pain and has been adapted to treat provoked vestibulodynia via repeated sequences of contraction/relaxation of the pelvic floor muscles. Its main objective is to decrease hypertonicity, which is suspected of being partly responsible of exacerbating vulvo-vaginal pain.
14,56,57 Glazer et al 42 conducted a case study with 1 woman who had received biofeedback treatment. At follow-up, the patient reported complete pain relief. Bergeron et al 43 retrospectively studied physical therapy (including biofeedback) for the rehabilitation of the pelvic floor and found a 52% pain reduction success rate and a significant improvement of women's sexual functioning. In McKay et al's 44 prospective biofeedback study, 83% of women indicated a significant decrease of their pain, and 83% of the latter indicated having become sexually active after treatment. Finally, Danielsson et al 45 conducted the only study that compared the efficacy of a behavioral treatment (biofeedback) to that of a medical treatment (topical lidocaine) and did so with a randomized clinical trial. The 2 treatments significantly improved pain thresholds, quality of life, and psychosexual functioning of participants. Nevertheless, no significant difference was found between the 2 treatments, which may be due to a lack of statistical power or to low compliance by the biofeedback group.
Cognitive-behavioral therapy for provoked vestibulodynia aims to decrease pain, reduce fear of pain, and reestablish satisfying sexual functioning. ter Kuile and Weijenborg 46 prospectively evaluated the efficacy of this therapy in a group format with a large sample. The authors reported that participants had a significant reduction of dyspareunia, in addition to a significant improvement of sexual satisfaction and perceived pain control from pretreatment to posttreatment. However, no significant difference was reported with regard to marital satisfaction and psychologic distress, probably because these did not reach clinical thresholds at pretreatment.
Bergeron et al 27 conducted the only randomized study that examined cognitive-behavioral therapy. More specifically, participants were randomized either to CBGT, biofeedback, or vestibulectomy. Findings indicate that the participants of the 3 treatment groups reported significant improvements of their pain. The average percentage of pain reduction was 47% to 70% for vestibulectomy, 19% to 35% for biofeedback, and 21% to 38% for CBGT. Vestibulectomy was thus shown to be significantly more successful than the 2 other treatments in terms of pain reduction. Nevertheless, the 3 treatments resulted in equally significant psychosexual functioning improvements. Last, the CBGT group presented a significantly lower attrition rate than the vestibulectomy group and participants were more satisfied with their treatment than those who took part in biofeedback.
As shown in Table 3 , the great majority of behavioral and cognitive-behavioral treatment studies have the same methodological limitations than the medical and surgical treatment studies (eg, no randomization, no double-blind evaluation). However, the majority of behavioral and cognitive-behavioral treatment studies used objective measures for evaluating pain and sexual function, described their sample well, and conducted pretreatment and posttreatment evaluations of pain and sexual function. Although treatment compliance was measured more often in the behavioral treatment studies than in the medical ones, it was not always reported in the article, complicating the interpretation of results. Other controlled studies are required to further corroborate the results obtained so far and to identify predictors of treatment outcome. Given that behavioral treatments lead to similar therapeutic success than medical interventions, and given the documented absence of associated negative side effects, patients might benefit from being more informed about these treatment options.
Alternative Treatments
Though no studies on alternative treatments figured in the review of Bergeron et al, 14 5 studies have since been published (Table 3) . First, Fowler 47 prospectively evaluated a hypoallergenic vulvar hygiene program comprised of 14 recommendations specifically targeted toward vestibulodynia. Results showed that 20% of participants had a complete response to the program whereas 57% had a partial response. Unfortunately, due to the combination of many strategies of pain relief, it is impossible to identify the unique impact of each of these. Danielsson et al 48 prospectively examined the efficacy of acupuncture, showing that participants reported a significant improvement of their quality of life after treatment. Regrettably, pain results were not included in their article because the evaluation method was found to be ineffective.
Kandyba and Binik 49 conducted a case study with 1 woman having received hypnotherapy. At follow-up, the woman reported complete pain relief, a nearly complete reduction of her anticipatory anxiety, and a feeling of personal control over her pain. Though these results are encouraging, the participant had received physical therapy sessions before and during the hypnotherapy treatment. Pukall et al 50 led a similar hypnotherapy study in which the 8 women showed a significant reduction of pain and a significant improvement in sexual satisfaction. Last, although certain treatment guidelines for provoked vestibulodynia suggest a low-oxalate diet, 12 only one study of that treatment was identified since 1996. Greenstein et al 51 showed that only one of 7 participants experienced an improvement of her symptoms of vestibulodynia and was capable of having pain-free sexual intercourse after treatment.
The methodological limitations of the 5 alternative treatment studies are the same as those of the preceding sections (eg, no randomization, no control group) (Table 3) . Furthermore, the small number of participants included in these studies clearly shows that the evaluation of these treatments is still in its preliminary phase.
DISCUSSION
To date, attempts to treat provoked vestibulodynia have largely been conducted on a trial-and-error basis. Despite some 40-treatment studies published since 1996, it remains difficult to choose the most adequate intervention for any given patient. Indeed, the lack of randomized clinical trials and various other methodological weaknesses complicate the conclusions that can be drawn concerning the efficacy of available treatments. Nevertheless, the state of research on provoked vestibulodynia has progressed significantly over the past decade. In fact, at the time of Bergeron et al's 14 review, the great majority of knowledge was based on case studies and retrospective designs. Today, the research is comprised of more prospective studies and of a small number of randomized clinical trials.
On the basis of the results of randomized and prospective studies, vestibulectomy still seems to be the most efficacious treatment option to date, although one that cannot be recommended as a first line intervention given its degree of invasiveness. More specifically, surgical treatment was shown to be twice as efficacious as behavioral treatments in the randomized outcome study by Bergeron et al, 27 and it continually obtains the best success rates in prospective studies. However, these 17 and minor postsurgical complications. 17, 18, 20, 22, 25, 26 Future studies need to document and define possible negative side effects more systematically.
Despite the fact that they are offered as the predominant treatment choice, medical interventions remain understudied. Results from the small number of clinical trials are somewhat discouraging, yet the uncontrolled prospective studies show that daily applications of lidocaine and corticosteroid-lidocaine injections provide considerable relief to women with provoked vestibulodynia, while being minimally invasive. Thus, these medical treatments merit further investigation by way of placebocontrolled randomized clinical trials.
Biofeedback and cognitive-behavioral therapy are promising noninvasive treatments. According to prospective studies, these 2 therapeutic modalities not only have success rates similar to certain medical treatments, but they also have the advantage of targeting both the reduction of pain and its psychosexual consequences (eg, reduced desire and arousal). 6, [58] [59] [60] [61] [62] Finally, alternative treatments should be the object of more large scale prospective studies so that their efficacy and safety can be determined.
The methodology of future research would benefit from some improvements. Namely, given the large placebo effect detected in experimental studies conducted so far, 32, 34 studies should include a placebo group whenever possible (eg, medical treatments). Moreover, to quantify the changes in pain after treatment, validated measures need to be included (eg, the McGill Pain Questionnaire 54 ) rather than home-made, dichotomous scales (eg, success or failure) still used in most of the studies. In addition, pain evaluations must not only be conducted posttreatment but also pretreatment to determine the scope of the change effected by the intervention. To verify whether the therapeutic benefits are maintained over the long term, researchers should also ensure that the length of follow-ups is adequate (eg, follow-up of at least 6 mo). Last, vestibulodynia goes far beyond the experience of pain and has serious consequences on sexual function, dyadic adjustment, psychologic well-being, and quality of life. [5] [6] [7] Nevertheless, studies that measure the impact of treatment on these variables are rare-an important limitation that should be addressed in future studies.
From a theoretical standpoint, research on the treatment of provoked vestibulodynia still suffers from a lack of consideration of the biopsychosocial approach presently accepted and successfully used in the field of chronic and recurrent pain. 63 This model not only takes into account the importance of biomedical factors involved in the development, maintenance, and exacerbation of pain, but also of cognitive, affective, behavioral, and interpersonal factors. However, to date, the great majority of treatment studies on vestibulodynia adopt a unidimensional biomedical perspective despite the fact that many authors recommend combining medical with cognitive-behavioral or behavioral treatments. 20, 24, 27, 31, 35, 45, 47 Consequently, by targeting the multiple aspects of vestibulodynia rather than the pain in an isolated way, a multimodal approach could prove optimal. In fact, the combination of treatments could have a cumulative effect with regard to efficacy and could thus (1) become an alternative to surgery for patients who find this modality too invasive or (2) allow to improve the success rates of surgery by combining it with, for example, a behavioral intervention. 64 The next generation of treatment studies must try to determine whether a multimodal approach is more advantageous than the unidimensional one which still prevails in most centers, while taking into consideration the multiple domains of functioning (eg, quality of life, sexual satisfaction) that are affected by this distressing urogenital pain problem.
